TIR-Domain-Containing Adaptor-Inducing Interferon-β (TRIF) Mediates Antibacterial Defense during Gram-Negative Pneumonia by Inducing Interferon-γ

Klebsiella pneumoniae is an important cause of Gram-negative pneumonia and sepsis. Mice deficient for TIR-domain-containing adaptor-inducing interferon-β (TRIF) demonstrate enhanced bacterial growth and dissemination during Klebsiella pneumonia. We show here that the impaired antibacterial defense of TRIF mutant mice is associated with absent interferon (IFN)-γ production in the lungs. IFN-γ production by splenocytes in response to K. pneumoniae in vitro was critically dependent on Toll-like receptor 4 (TLR4), the common TLR adaptor myeloid differentiation primary response gene (MyD88) and TRIF. Reconstitution of TRIF mutant mice with recombinant IFN-γ via the airways reduced bacterial loads in lungs and distant body sites to levels measured in wild-type mice, and partially restored pulmonary cytokine levels. The IFN-γ-induced, improved, enhanced antibacterial response in TRIF mutant mice occurred at the expense of increased hepatocellular injury. These data indicate that TRIF mediates antibacterial defense during Gram-negative pneumonia, at least in part, by inducing IFN-γ at the primary site of infection.

[1]  M. Netea,et al.  Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series , 2014, BMC Infectious Diseases.

[2]  O. Pappo,et al.  Bone Marrow and Nonbone Marrow Toll Like Receptor 4 Regulate Acute Hepatic Injury Induced by Endotoxemia , 2013, PloS one.

[3]  M. Falagas,et al.  Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[4]  T. van der Poll,et al.  Differential roles of MyD88 and TRIF in hematopoietic and resident cells during murine gram-negative pneumonia. , 2012, The Journal of infectious diseases.

[5]  T. van der Poll,et al.  Myeloid-Related Protein-14 Contributes to Protective Immunity in Gram-Negative Pneumonia Derived Sepsis , 2012, PLoS pathogens.

[6]  J. Li,et al.  Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  T. van der Poll,et al.  Delineation of the Role of Toll-like Receptor Signaling during Peritonitis by a Gradually Growing Pathogenic Escherichia coli , 2011, The Journal of Biological Chemistry.

[8]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[9]  F. Aversa,et al.  Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO , 2010, Cellular and Molecular Immunology.

[10]  T. van der Poll,et al.  Host defence during Klebsiella pneumonia relies on haematopoietic-expressed Toll-like receptors 4 and 2 , 2010, European Respiratory Journal.

[11]  T. Tsujimoto,et al.  Salvage effect of E5564, Toll‐like receptor 4 antagonist on d‐galactosamine and lipopolysaccharide‐induced acute liver failure in rats , 2010, Journal of gastroenterology and hepatology.

[12]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[13]  S. Batra,et al.  Both TRIF- and MyD88-Dependent Signaling Contribute to Host Defense against Pulmonary Klebsiella Infection1 , 2009, The Journal of Immunology.

[14]  M. Eisenhut Acute lower respiratory tract infection. , 2008, The New England journal of medicine.

[15]  L. González-Méndez,et al.  Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study , 2008, BMC infectious diseases.

[16]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[17]  S. Akira,et al.  References Subscriptions Permissions Email Alerts TLR9 Is Required for Protective Innate Immunity in Gram-Negative Bacterial Pneumonia: Role of Dendritic Cells , 2013 .

[18]  D. Aronoff,et al.  Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. , 2007, American journal of respiratory cell and molecular biology.

[19]  P. Carmeliet,et al.  Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. , 2007, Blood.

[20]  J. Reiser,et al.  Conditional expression of interferon-gamma to enhance host responses to pulmonary bacterial infection. , 2006, Pulmonary pharmacology & therapeutics.

[21]  Marin H Kollef,et al.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. , 2005, Chest.

[22]  K. Schroder,et al.  Interferon‐γ: an overview of signals, mechanisms and functions , 2004 .

[23]  T. Standiford,et al.  Anti-Tumor Necrosis Factor-&agr; Therapy During Murine Klebsiella pneumoniae Bacteremia: Increased Mortality in the Absence of Liver Injury , 2003, Shock.

[24]  Jiahuai Han,et al.  Identification of Lps2 as a key transducer of MyD88-independent TIR signalling , 2003, Nature.

[25]  T. Standiford,et al.  Divergent Role of Gamma Interferon in a Murine Model of Pulmonary versus Systemic Klebsiella pneumoniae Infection , 2002, Infection and Immunity.

[26]  Y. Iwakura,et al.  Role of interferon-gamma in inflammatory responses in murine respiratory infection with Legionella pneumophila. , 2002, Journal of medical microbiology.

[27]  Y. Iwakura,et al.  Protection against pulmonary infection with Klebsiella pneumoniae in mice by interferon-gamma through activation of phagocytic cells and stimulation of production of other cytokines. , 2001, Journal of medical microbiology.

[28]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[29]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[30]  S. Akira,et al.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. , 1998, Immunity.

[31]  J. Shellito,et al.  Adenoviral-mediated interferon-gamma gene therapy augments pulmonary host defense of ethanol-treated rats. , 1998, Alcoholism, clinical and experimental research.

[32]  Murray Hw Interferon-gamma in infection and immunoparalysis. , 1996 .

[33]  H. D. Liggitt,et al.  Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon , 1991, Infection and immunity.

[34]  R. D. Beer,et al.  Cell-specific pattern recognition receptor signaling in antibacterial defense , 2015 .

[35]  R. Reljic,et al.  Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. , 2009, Tuberculosis.

[36]  R. Wunderink,et al.  Adjunctive Therapy in Community-Acquired Pneumonia , 2009, Seminars in respiratory and critical care medicine.

[37]  A. Haque,et al.  A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. , 2007, The Journal of infectious diseases.

[38]  H. Murray Interferon-gamma in infection and immunoparalysis , 2005, Intensive Care Medicine.

[39]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.